Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants

Show simple item record

dc.contributor.author Mittal, Anshumali
dc.contributor.author Khattri, Arun
dc.contributor.author Verma, Vikash
dc.date.accessioned 2023-04-25T05:13:15Z
dc.date.available 2023-04-25T05:13:15Z
dc.date.issued 2022-02
dc.identifier.issn 15537366
dc.identifier.uri http://localhost:8080/xmlui/handle/123456789/2238
dc.description This paper is submitted by the author of IIT (BHU), Varanasi, India en_US
dc.description.abstract The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)virus is continuously evolving, and this poses a major threat to antibody therapies and currently authorized Coronavirus Disease 2019 (COVID-19) vaccines. It is therefore of utmost importance to investigate and predict the putative mutations on the spike protein that confer immune evasion. Antibodies are key components of the human immune system's response to SARSCoV- 2, and the spike protein is a prime target of neutralizing antibodies (nAbs) as it plays critical roles in host cell recognition, fusion, and virus entry. The potency of therapeutic antibodies and vaccines partly depends on how readily the virus can escape neutralization. Recent structural and functional studies have mapped the epitope landscape of nAbs on the spike protein, which illustrates the footprints of several nAbs and the site of escape mutations. In this review, we discuss (1) the emerging SARS-CoV-2 variants; (2) the structural basis for antibody-mediated neutralization of SARS-CoV-2 and nAb classification; and (3) identification of the RBD escape mutations for several antibodies that resist antibody binding and neutralization. These escape maps are a valuable tool to predict SARS-CoV-2 fitness, and in conjunction with the structures of the spike-nAb complex, they can be utilized to facilitate the rational design of escape-resistant antibody therapeutics and vaccines. en_US
dc.language.iso en_US en_US
dc.publisher Public Library of Science en_US
dc.relation.ispartofseries PLoS Pathogens;Volume 18, Issue 2
dc.subject Coronavirus spike glycoprotein en_US
dc.subject Antigenic Variation en_US
dc.subject Antibodies, Viral en_US
dc.subject Antibodies en_US
dc.subject COVID-19 en_US
dc.subject COVID-19 Vaccines en_US
dc.subject Mutation en_US
dc.subject Spike Glycoprotein en_US
dc.subject Antibodies, Neutralizing; Antibodies, Viral; Antigenic Variation; COVID-19; COVID-19 Vaccines; Epitopes; Humans; Immune Evasion; Models, Structural; Mutation; SARS-CoV-2; Spike Glycoprotein, Coronavirus en_US
dc.title Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search in IDR


Advanced Search

Browse

My Account